X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
177Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other 177Lu-FAP-ligands.
Lead Product(s): 177Lu-OncoFAP-23
Therapeutic Area: Oncology Product Name: 177Lu-OncoFAP-23
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Philochem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 13, 2022
Details:
177Lu-FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach medical radioisotopes, such as lutetium-177 for therapeutic use, or gallium-68 for imaging use.
Lead Product(s): 177Lu-FAP-2286
Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Recipient: Clovis Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 21, 2022
Details:
177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.
Lead Product(s): No-Carrier-Added Lutetium-177
Therapeutic Area: Oncology Product Name: n.c.a 177 Lu
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CPDC Centre for Probe Development and Commercialization
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Seibersdorf Labor, a GMP Contract manufacturing of radiopharmaceuticals, a global leader in the development, production, and commercialization of radiopharmaceuticals, will produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for distribution in Europe.
Lead Product(s): No-carrier-added Lutetium-177
Therapeutic Area: Oncology Product Name: 177Lu n.c.a
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Seibersdorf Labor GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
